Specifically, TREM2 in TAMs promotes tumor progression in colorectal carcinoma [22], ovarian carcinoma [23] and hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) [24] by remodeling the landscape of tumor-infiltrating myeloid cells and weakening the anti-tumor ability of CD8+ T cells. Here, CD8A is linked to hepatocellular carcinoma.